THE PURE-PLAY DERMATOLOGY CATEGORY LEADER
We deliver a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing dermatology market. Our brands hold leading market positions in their respective product categories and are supported by science-based product differentiation and premium positioning.
Our ambition: to become the leading dermatology company in the world.
2022 HIGHLIGHTS
European launch of Alluzience®
the first ready-to-use liquid form of botulinum toxin type A, indicated for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines
Alastin Skincare® multiple launches
Launches of multiple breakthrough innovations across the Alastin Skincare® line
Cetaphil® 75 years
Celebration of 75 years of sensitive skincare leadership with Cetaphil®
Completion of the ARCADIA program
which included two phase III clinical trials demonstrating the efficacy and safety of nemolizumab in adolescent and adult patients with moderate to severe atopic dermatitis
Publication of positive data from a phase III OLYMPIA 2 trial
demonstrating the efficacy and safety of nemolizumab in patients with prurigo nodularis
Expansion of the production site in Uppsala, Sweden
to meet the increasing global demand for injectable aesthetcis products and provide additional capacity for new products in development
Publication of positive phase III results for RelabotulinumtoxinA
a unique liquid ready-to-use RelabotulinumtoxinA for the treatment of glabellar lines and lateral canthal lines
Creation of the Galderma Sensitive Skincare Faculty
a global expert group to improve understanding and management of sensitive skin
Launch of Twyneo® Cream in the U.S.
the first ever tretinoin and benzoyl peroxide combination to treat facial acne
Exploring opportunities to build a fifth manufacturing plant in Singapore
to expand our manufacturing and innovation footprint in the Asia-Pacific region
New phase IV data confirming the effectiveness of Restylane®
all patients achieved treatment aims and indicated high subject satisfaction
Celebration of 10 years of partnership with Camp Wonder
a medically staffed summer camp program for children aged seven to sixteen with serious skin diseases
FOREWORD FROM GALDERMA CEO
"2022 was another remarkable year in Galderma’s history. We delivered strong growth and reached several important milestones while moving closer to our ambition to be the category leader in dermatology.
In 2022, we achieved blockbuster status for the first time – in excess of 1 B USD net sales – in three of our product platforms, two in Injectable Aesthetics and one in Dermatological Skincare. We are making progress against our goals by following three key growth drivers: a relentless focus on commercial execution, portfolio and geographic expansion and delivering notable pipeline innovations and launches.
Galderma is now positioned to accelerate our growth even further. Our focus will be on strengthening our leadership position and exploring further opportunities to advance our portfolio and our pipeline.
We are on a remarkable growth journey driven by a responsibility to deliver innovation on behalf of healthcare professionals, patients and consumers. We will continue to do so with great pride in our purpose: advancing dermatology for every skin story.”
Flemming Ørnskov, M.D., MPH
Chief Executive Officer
Galderma
OUR UNIQUE INTEGRATED DERMATOLOGY STRATEGY
Our unique Integrated Dermatology Strategy is a key differentiator for Galderma by creating greater consumer, patient and healthcare professional engagement, generating better customer insights and delivering continuous innovation.
This strategy is driving a competitive advantage and fueling strong growth for Galderma by activating considerable global synergies in our commercial execution, Research & Development (R&D) platform and other functions.
UNDERSTAND OUR INTEGRATED DERMATOLOGY STRATEGY
WE DEMONSTRATED A SUSTAINED GROWTH MOMENTUM IN 2022
We delivered a very strong commercial and financial performance in 2022, despite a challenging external environment. Overall, we achieved double-digit sales growth as well as double-digit Core EBITDA growth.
Across our businesses, we had a particularly strong global performance in Injectable Aesthetics and Dermatological Skincare – off-setting the anticipated decline in Therapeutic Dermatology due to loss of exclusivity for two key brands in the U.S., as well as increased competition. Within Injectable Aesthetics, we outperformed the market with double-digit growth and market share gains across the portfolio. We also achieved strong double-digit growth in our Dermatological Skincare business, which significantly out-paced the overall market growth. In Therapeutic Dermatology, we made clear progress in the clinical development and pre-commercial support for our key biologic asset nemolizumab.
INJECTABLE AESTHETICS
One of our priorities in our pipeline is RelabotulinumtoxinA, a novel liquid formulation of botulinum toxin A. In 2022, we announced positive topline results from two phase III clinical studies demonstrating that RelabotulinumtoxinA improves both glabellar (frown) lines and lateral canthal lines (crow’s feet) with a rapid onset of action and a long duration. We also unveiled new data that demonstrates high aesthetic improvement and patient satisfaction across our innovative portfolio. These results included new phase IV data confirming the effectiveness and natural-looking effects of the Restylane range of hyaluronic acid fillers.
DERMATOLOGICAL SKINCARE
Over the past seven decades, Cetaphil’s portfolio has evolved to address a variety of complex sensitive skin needs. Innovation remains core to the brand’s ethos. In 2022, we developed 12 new products and designed a regimen for those suffering from the itch-scratch cycle of eczema. Following the acquisition of Alastin Skincare, we added new innovative formulas to our unique portfolio of products.
THERAPEUTIC DERMATOLOGY
We aim to become the leader in specialty and rare dermatology by prioritizing biotechnologies for injectable and oral products. One of our core projects is the development of nemolizumab, an investigational therapy for atopic dermatitis, prurigo nodularis and pruritus (itch) associated with chronic kidney disease. Nemolizumab is a first-in-class, investigational monoclonal antibody targeting the IL-31 receptor alpha. This receptor plays a central role in causing pruritus and skin inflammation. In 2022, we announced that our phase III OLYMPIA 2 trial met all primary endpoints and key secondary endpoints.
COMMITTED TO GROWTH THROUGH STAKEHOLDER ENGAGEMEENT
In 2022, we significantly increased our scientific engagement and consumer outreach. Through our Galderma Aesthetics Injectors Network (GAIN) program, we directly reached more than 100,000 aesthetics professionals around the world. We increased the visibility of our scientific research as Galderma data featured prominently at numerous key international medical congresses.
We launched a new global consumer campaign in support of the 75th anniversary of Cetaphil, and we reached millions of people via a social media campaign in support of Sensitive Skin Awareness month.
PUTTING CUSTOMERS' NEEDS FIRST
We have fundamentally re-shaped the way we engage with our key audiences. We place them at the center of virtually everything we do. Through our salesforce, we implement a high-touch and customer-centric engagement model. Using various digital engagement tools, we listen to our customers’ needs and continuously improve our engagement model accordingly. Finally, we provide our customers with critical, science-backed information about our products and service offerings. We believe this allows our customers to place trust in our brands, which supports our future growth.
GET TO KNOW OUR SYNERGISTIC, SCIENCE-BASED FLAGSHIP BRANDS
SHAPING THE FUTURE OF DERMATOLOGY
Our commitment to advancing dermatology for every skin story is grounded in over 40 years of science-led investment and innovation. Since we became a standalone company in 2019, we have significantly increased our investment in research and development to develop key clinical assets. Our late-stage pipeline assets include nemolizumab, our biologic asset with significant commercial potential, and RelabotulinumtoxinA (QM-1114), our unique liquid, ready-to-use neuromodulator developed with a proprietary strain of botulinum toxin A. Both these assets represent potentially transformative products in their respective categories. We also continue to promote scientific innovation for products within our existing portfolio.
-
A first-in-class investigational monoclonal antibody with the potential to be a key therapeutic solution for patients suffering from moderate to severe prurigo prurigo nodularis.
-
The first ready-to-use liquid form of botulinum toxin type A (BoNT-A) approved for aesthetic use in Europe.
-
A range of innovative, clinically tested skincare products that correct, protect and maintain healthy skin for a lifetime. They are the latest additions to our synergistic portfolio of award-winning, physician-dispensed brands.
DIVE DEEPER INTO OUR SCIENCE
MANUFACTURING KEEPS PACE WITH GROWING GLOBAL DEMAND
To enable innovation at scale and support the rapid growth of our business, our operations embrace the most advanced manufacturing technologies available.
Our four manufacturing plants are strategically located in Canada, Sweden, France and Brazil, serving more than 90 countries with over 280 million units produced annually.
In 2022, we made major announcements about the expansion of our manufacturing footprint in response to increasing global demand for science-based premium dermatology brands. In Uppsala, Sweden, we announced a significant investment of approximately 200 million USD in a new facility. This site will help meet the increasing global demand for Injectable Aesthetics products and provide additional capacity for new products currently in development. Our Alby-sur-Chéran, France site serves all markets except the U.S. with topicals – both over-the-counter (OTC) and prescription medicine – and supplies brands such as Differin, Aklief and Epiduo. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil.
SOME HIGHLIGHTS
90 Countries
We serve more than 90 countries globally with over 280 million units produced a year.
Approximately 75%
of our units sold are produced in-house in four manufacturing facilities.
Over 1,600 colleagues
in manufacturing, commercial quality and supply chain functions work at our four manufacturing plants.
99% renewable
Currently, more than 99% of renewable electricity is supplied to our four factories, and two are certified Carbon Neutral.
Low Injury Rate
We have succeeded in maintaining a low global Recordable Injury Rate (1.1 per million working hours in 2022), meaning no severe, irreversible injuries were recorded.
50+ manufacturing plant inspections
As a demonstration of our commitment to quality and safety, we have successfully completed more than 50 manufacturing plant inspections over the past five years.
3 of 4
factory sites use 100% renewable electricity from a combination of solar, wind, hydropower, geothermal, biofuel and biomass.
100% renewable electricity by 2024
Our fourth factory is on track to be powered by 100% renewable electricity by 2024.
Zero waste-to-landfill
Our four factories achieved zero waste-to-landfill ahead of our initial plan.
DISCOVER OUR APPROACH TO MANUFACTURING
HIGH-PERFORMING TEAMS SHARING A HIGHER PURPOSE
Our purpose, underpinned by Galderma’s four commitments inspires and motivates our teams every day. It reminds us continuously why we do what we do, and requires each of us to act with integrity and unwavering dedication.
OUR COMMITMENTS
At Galderma, we expect our employees to uphold four key commitments as we strive to become the leading dermatology company in the world. These commitments are at the heart of the culture that impacts how we work and serve people every day:
• We listen to consumers, patients and customers, always putting their needs first
• We innovate to stay at the cutting edge, embracing our heritage in dermatology
• We collaborate openly to empower each other and our partners
• We rise above expectations to achieve outstanding results
KEY FACTS
13
Galderma affiliates certified as “Great Place to Work®” as of December 31, 2022.
56%
women in our workforce.
FIND OUT ABOUT CAREERS AT GALDERMA
OUR ESG JOURNEY
We are a responsible business with the ambition to become the leading dermatology company in the world. We are also committed to maintaining Environmental, Social and Governance (ESG) regulations, as these are integral to our growth outlook and deeply rooted in all dimensions of our business.
Our ESG journey is focused on four key stakeholder groups: Employees, Patients & Consumers, Healthcare Professionals & Customers, and Society. For each stakeholder group, we are creating a tailored ESG roadmap with concrete actions and associated indicators.
GET INSIGHTS INTO OUR ESG ROADMAP
